Search results for "Gastroenterologia"

showing 10 items of 310 documents

SELF-EXPANDABLE METAL STENT PLACEMENT FOR CLOSURE OF A LEAK AFTER TOTAL GASTRECTOMY FOR GASTRIC CANCER: REPORT ON THREE CASES AND REVIEW OF THE LITER…

2014

In the setting of the curative oncological surgery, the gastric surgery is exposed to complicated upper gastrointestinal leaks, and consequently the management of this problem has become more critically focused than was previously possible. We report here three cases of placement of a partially silicone-coated SEMS (Evolution Controlled Release Esophageal Stent System, Cook Medical, Winston-Salem, NC, USA) in patients who underwent total gastrectomy with Roux-en-Y end-to-side esophagojejunostomy for a gastric adenocarcinoma. The promising results of our report, despite the small number of patients, suggest that early stenting (through a partially silicone-coated SEMS) is a feasible alternat…

Historymedicine.medical_specialtyLeakSettore MED/12 - GastroenterologiaPolymers and PlasticsSelf expandablebusiness.industrymedicine.medical_treatmentCancerCase ReportAnastomosismedicine.diseaseIndustrial and Manufacturing EngineeringSurgeryStent placementSettore MED/18 - Chirurgia GeneraleEsophageal stentmedicinelcsh:Diseases of the digestive system. GastroenterologyGastrectomylcsh:RC799-869Business and International ManagementProspective cohort studybusinessGastric cencer self-expandle metal stent palliation endoscopy
researchProduct

Correlation between IgA tissue transglutaminase antibody ratio and histological finding in celiac disease.

2011

OBJECTIVES: Positivity of both immunoglobulin A anti-tissue transglutaminase (TTG) and anti-endomysium antibodies (EMA) has a positive predictive value of nearly 100% for celiac disease (CD). The objective of the present study was to evaluate whether patients of any age, with high pretest probability of CD and high titre of anti-TTG and EMA positivity, have a high probability of intestinal damage and may not require the biopsy for final diagnosis. METHODS: A retrospective analysis of 412 consecutively referred patients, age range 10 months to 72 years, who underwent small-bowel biopsy for suspicion of CD and positivity to both anti-TTG and EMA, was performed at 4 Italian centers. Biopsies w…

Immunoglobulin AAdultMalemedicine.medical_specialtyPathologyAdolescentTissue transglutaminaseDuodenumBiopsySettore MED/08 - Anatomia PatologicaGastroenterologySeverity of Illness IndexCoeliac diseaseStatistics NonparametricYoung AdultCoeliac disease Transglutaminase antibodyGTP-Binding ProteinsPredictive Value of TestsInternal medicineSeverity of illnessBiopsymedicineHumansProtein Glutamine gamma Glutamyltransferase 2ChildAgedRetrospective StudiesSettore MED/12 - GastroenterologiaTransglutaminasesbiologymedicine.diagnostic_testbusiness.industryMusclesGastroenterologyInfantRetrospective cohort studyMiddle Agedmedicine.diseaseImmunoglobulin APre- and post-test probabilityCeliac DiseaseLogistic ModelsPredictive value of testsChild PreschoolPediatrics Perinatology and Child Healthbiology.proteinFemalebusinessJournal of pediatric gastroenterology and nutrition
researchProduct

Liver disease in chelated transfusion-dependent thalassemics: the role of iron overload and chronic hepatitis C.

2008

Abstract Iron overload and hepatitis virus C infection cause liver fibrosis in thalassemics. In a monocentric retrospective analysis of liver disease in a cohort of 191 transfusion-dependent thalassemics, in 126 patients who had undergone liver biopsy (mean age 17.2 years; 58 hepatitis virus C-RNA positive and 68 hepatitis virus C-RNA negative) the liver iron concentration (median 2.4 mg/gr dry liver weight) was closely related to serum ferritin levels (R = 0.58; p<0.0001). Male gender (OR 4.12) and serum hepatitis virus C-RNA positivity (OR 11.04) were independent risk factors for advanced liver fibrosis. The majority of hepatitis virus C-RNA negative patients with low iron load did not de…

Iron HCV thalassemicsSettore MED/12 - GastroenterologiaSettore MED/08 - Anatomia Patologica
researchProduct

Practice guidelines for the treatment of hepatitis C: recommendations from an AISF/SIMIT/SIMAST Expert Opinion Meeting.

2010

It is increasingly clear that a tailored therapeutic approach to patients with hepatitis C virus infection is needed. Success rates in difficult to treat and low-responsive hepatitis C virus patients are not completely satisfactory, and there is the need to optimise treatment duration and intensity in patients with the highest likelihood of response. In addition, the management of special patient categories originally excluded from phase III registration trials needs to be critically re-evaluated. This article reports the recommendations for the treatment of hepatitis C virus infection on an individual basis, drafted by experts of three scientific societies.

Liver CirrhosisANTIVIRAL TREATMENTHuman immunodeficiency virus (HIV)HIV InfectionsHepacivirusANTIVIRAL THERAPY; PEGYLATED INTERFERON-ALPHA-2B; LIVER-TRANSPLANTATION; PEGINTERFERON ALPHA-2A; HIV-INFECTED PATIENTS; VIRUS-COINFECTED PATIENTS; RAPID VIROLOGICAL RESPONSEAntiviral therapymedicine.disease_causeGastroenterologyPolyethylene GlycolsHBVguidelinesAcute hepatitisChronic hepatitisSettore MED/12 - Gastroenterologialiver transplantationGastroenterologyAntiviral therapyHepatitis CVIRUS-COINFECTED PATIENTSLIVER-TRANSPLANTATIONHepatitis CRecombinant Proteinsacute hepatitis; antiviral therapy; chronic hepatitis; cirrhosis; elderly patients; hbv; hcv; hdv; hiv; liver transplantationCLINICAL PRACTICE GUIDELINESCirrhosisHCVDrug Therapy CombinationAntiviral therapy Acute hepatitis Chronic hepatitisCirrhosis Elderly patients HBV HCV HDV HIV Liver transplantationElderly patientAcute hepatitiAcute hepatitismedicine.medical_specialtyGenotypePEGINTERFERON ALPHA-2AAlpha interferonHIV-INFECTED PATIENTSInterferon alpha-2CHRONIC HEPATITIS CAntiviral AgentsHepatitis B ChronicChronic hepatitisInternal medicineHDVDrug Resistance ViralRibavirinmedicineHumansPEGYLATED INTERFERON-ALPHA-2BCirrhosiHepatologybusiness.industrySettore MED/09 - MEDICINA INTERNAInterferon-alphaHIVHepatitis C Chronicmedicine.diseaseElderly patientsFamily medicineExpert opinionAntiviral therapy; Acute hepatitis; Chronic hepatitis; Cirrhosis; Elderly patients; HBV; HCV; HDV; HIV; liver transplantationChronic hepatitiRAPID VIROLOGICAL RESPONSEbusinessCHRONIC HEPATITIS C; ANTIVIRAL TREATMENT; CLINICAL PRACTICE GUIDELINES
researchProduct

The Hepatic Expression of Vitamin D Receptor Is Inversely Associated With the Severity of Liver Damage in Genotype 1 Chronic Hepatitis C Patients

2015

BACKGROUND/AIMS: Low 25-hydroxyvitamin D serum levels have been associated with the severity of liver fibrosis in genotype 1 chronic hepatitis C patients (G1CHC), and experimental evidence suggested a hepatoprotective role of vitamin D via interaction with hepatic vitamin D receptor (VDR). We assessed the hepatic expression of VDR protein and its association with liver disease severity. METHODS: Ninety-one consecutive patients with biopsy-proven G1CHC and available frozen liver tissue were evaluated. Ten subjects without chronic liver diseases and nine patients with autoimmune hepatitis served as controls. The hepatic expression of VDR protein was assessed by Western blot for quantification…

Liver CirrhosisAdultMaleLiver damagemedicine.medical_specialtyLiver CirrhosiEndocrinology Diabetes and MetabolismClinical BiochemistryVDR liver fibrosisLiver damage; VDR liver fibrosisAutoimmune hepatitisBiologySeverity of Illness IndexBiochemistryCalcitriol receptorLiver diseaseEndocrinologyWestern blotFibrosisInternal medicinemedicineVitamin D and neurologyHumansSettore MED/12 - Gastroenterologiamedicine.diagnostic_testBiochemistry (medical)Hepatitis CHepatitis C ChronicMiddle Agedmedicine.diseaseEndocrinologyLiverVitamin D3 ReceptorReceptors CalcitriolFemaleHumanThe Journal of Clinical Endocrinology &amp; Metabolism
researchProduct

Treatment of hepatitis C virus infection with direct-acting antiviral drugs is safe and effective in patients with hemoglobinopathies

2017

Progression of liver fibrosis in patients with hemoglobinopathies is strongly related to the severity of iron overload and the presence of chronic hepatitis C virus (HCV) infection. Effective iron chelation therapy and HCV infection eradication may prevent liver complications. The European Association for the Study of the Liver guidelines recommend interferon-free regimens for the treatment of HCV infection in patients with hemoglobinopathies. However, data regarding the use of direct-acting antiviral drugs (DAAs) in this patient population are few. This observational study evaluated the safety and efficacy of therapy with DAAs in an Italian cohort of patients with hemoglobinopathies, chron…

Liver CirrhosisAdultMalemedicine.medical_specialtyIron OverloadThalassemiaHepatitis C virusLiver CirrhosiIron Chelating Agentsmedicine.disease_causeAntiviral AgentsGastroenterologyVirus03 medical and health sciencesLiver disease0302 clinical medicineInternal medicinemedicinechronic hepatitis CHumansHematology hemoglobinopathies chronic hepatitis C direct antiviral agentsChelation therapyChronicAntiviral AgentSettore MED/12 - GastroenterologiaHematologybusiness.industrydirect antiviral agentsAdult; Antiviral Agents; Female; Hemoglobinopathies; Hepatitis C Chronic; Humans; Iron Chelating Agents; Iron Overload; Liver Cirrhosis; Male; Middle Aged; Treatment Outcome; HematologyHepatitis CHematologyHepatitis C ChronicMiddle Agedmedicine.diseaseHepatitis CHemoglobinopathiesHemoglobinopathieIron Chelating AgentTreatment Outcome030220 oncology & carcinogenesisImmunologyCohort030211 gastroenterology & hepatologyFemalebusinessHuman
researchProduct

Hepatitis C in the elderly: a multicentre cross-sectional study by the Italian Association for the Study of the Liver

2012

Background: The prevalence of hepatitis C virus infection increases with advancing age, but elderly hepatitis C virus patients remain an understudied population. Aim: To define the virological, epidemiological and clinical profiles of Italian outpatients aged 65 years and over infected by hepatitis C virus. Methods: We evaluated 1544 anti-hepatitis C virus positive patients aged >=65 years referred to 34 Italian outpatient specialty clinics over a two-year period. Results: The study population included 1134 (73%) early elderly (65-74 years) and 410 (27%) late elderly patients (>=75 years). Late elderly subjects were less likely to have their virus genotyped, their viral load assessed or a h…

Liver CirrhosisMaleAGED PATIENTS; EPIDEMIOLOGY; HCV INFECTION; LIVER DISEASES; ANTI-VIRAL TREATMENTEpidemiologyCross-sectional studyHepacivirusLIVER DISEASESmedicine.disease_causeLiver disease80 and overPrevalenceEPIDEMIOLOGYChronicAged patientsAged 80 and overeducation.field_of_studyhepatitis c elderly italyAge FactorsHCV INFECTIONGastroenterologyliver diseases; hepatitis c elderly italy; hcv infection; epidemiology; aged patientsAlanine TransaminaseHepatitis CViral LoadAGED PATIENTSHepatitis CHCV infectionItalyHCVAged patients; Epidemiology; HCV infection; Liver diseasesPopulation studyFemaleViral loadmedicine.medical_specialtyGenotypeSettore MED/12 - GASTROENTEROLOGIAHepatitis C virusPopulationgeriatricAntiviral AgentsInternal medicinemedicineHumanseducationSettore MED/42 - IGIENE GENERALE E APPLICATALiver diseasesAgedHepatologybusiness.industrySettore MED/09 - MEDICINA INTERNAHepatitis C ChronicHepatitis C AntibodiesHepatologymedicine.diseaseSurgeryCross-Sectional StudiesAged patients; Epidemiology; HCV infection; Liver diseases; Age Factors; Aged; Aged 80 and over; Alanine Transaminase; Antiviral Agents; Cross-Sectional Studies; Female; Genotype; Hepacivirus; Hepatitis C Antibodies; Hepatitis C Chronic; Humans; Italy; Liver Cirrhosis; Male; Prevalence; Viral Load; Gastroenterology; HepatologyANTI-VIRAL TREATMENTbusiness
researchProduct

Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents.

2018

Background &amp; Aims: Studies have produced conflicting results of the incidence of hepatocellular carcinoma (HCC) in patients with hepatitis C virus–associated cirrhosis treated with direct-acting antivirals (DAAs). Data from clinics are needed to accurately assess the occurrence rate of HCC in patients with cirrhosis in the real world. Methods: We collected data from a large prospective study of 2,249 consecutive patients (mean age = 65.4 years, 56.9% male) with hepatitis C virus–associated cirrhosis (90.5% with Child-Pugh class A and 9.5% with Child-Pugh class B) treated with DAAs from March 2015 through July 2016 at 22 academic and community liver centers in Sicily, Italy. HCC occurren…

Liver CirrhosisMaleCirrhosisSettore MED/09 - Medicina InternaSustained Virologic ResponseHepacivirusGastroenterology0302 clinical medicineRESIST-HCVRisk FactorsHepatocellular Carcinoma (HCC)MedicineLiver Cancer RiskProspective StudiesProspective cohort studySettore MED/12 - GastroenterologiaIncidence (epidemiology)IncidenceLiver NeoplasmsGastroenterologyHepatitis CMiddle AgedCirrhosis; Direct Antiviral Agents (DAAs); Hepatocellular Carcinoma (HCC); RESIST-HCV; Sustained Virological Response (SVR); hepatitis C Virus (HCV); liver cancer risk; reduction; sofosbuvirCirrhosisItalyLiver Neoplasm030220 oncology & carcinogenesisHepatocellular carcinomahepatitis C Virus (HCV)030211 gastroenterology & hepatologyFemaleHumanmedicine.medical_specialtyCarcinoma HepatocellularDirect Antiviral Agents (DAAs)Liver CirrhosiRESIST-HCV Liver Cancer Risk Reduction SofosbuvirAntiviral AgentsFollow-Up Studie03 medical and health sciencesInternal medicineHumansIn patientSustained Virological Response (SVR)AgedReductionAntiviral AgentHepaciviruHepatologybusiness.industryProportional hazards modelRisk FactorHepatitis C Chronicmedicine.diseasedigestive system diseasesProspective StudieChild-Pugh Class BSofosbuvirbusinessFollow-Up Studies
researchProduct

Severe reduction of blood lysosomal acid lipase activity in cryptogenic cirrhosis: A nationwide multicentre cohort study

2017

Background and aims Blood lysosomal acid lipase (LAL) is reduced in non-alcoholic steatohepatitis, which is the major cause of cryptogenic cirrhosis (CC); few data on LAL activity in CC do exist. We investigated LAL activity in a cohort of patients with liver cirrhosis. Methods This is a multicentre cohort study including 274 patients with liver cirrhosis of different aetiology from 19 centres of Internal Medicine, Gastroenterology and Hepatology distributed throughout Italy. Blood LAL activity (nmol/spot/h) was measured with dried blood spot extracts using Lalistat 2. Results Overall, 133 patients had CC, and 141 patients had cirrhosis by other causes (61 viral, 53 alcoholic, 20 alcoholic …

Liver CirrhosisMaleCryptogenic cirrhosis; Liver disease; Lysosomal acid lipase; PathogenesisCirrhosisCryptogenic cirrhosisCryptogenic cirrhosis; Liver disease; Lysosomal acid lipase; Pathogenesis; Cardiology and Cardiovascular MedicineComorbidityPathogenesisLysosonal acid lipase; non-alcoolic fatty liver disease; cirrhosis030204 cardiovascular system & hematologyGastroenterologyLiver disease0302 clinical medicineModel for End-Stage Liver DiseasePathogenesiRisk FactorsPrevalenceProspective cohort studyMultivariate AnalysiSettore MED/12 - GastroenterologiaMiddle AgedItalyCohortLinear Model030211 gastroenterology & hepatologyFemaleCardiology and Cardiovascular MedicineLiver diseaseHumanmedicine.medical_specialtyLiver CirrhosiDown-Regulation03 medical and health sciencesInternal medicineCryptogenic cirrhosis; Liver disease; Lysosomal acid lipase; Pathogenesis; Aged; Biomarkers; Chi-Square Distribution; Comorbidity; Cross-Sectional Studies; Down-Regulation; Dried Blood Spot Testing; Female; Humans; Italy; Linear Models; Liver Cirrhosis; Male; Middle Aged; Multivariate Analysis; Platelet Count; Prevalence; Risk Factors; Sterol EsterasemedicineLysosonal acid lipaseHumansnon-alcoolic fatty liver diseaseAgedCross-Sectional StudieChi-Square Distributionbusiness.industryPlatelet CountcirrhosisRisk FactorBiomarkerCholesterol ester storage diseaseHepatologySterol Esterasemedicine.diseaseCross-Sectional StudiesMultivariate AnalysisLysosomal acid lipaseLinear ModelsDried Blood Spot TestingSteatohepatitisbusinessCryptogenic cirrhosiBiomarkers
researchProduct

Genetic susceptibility of increased intestinal permeability is associated with progressive liver disease and diabetes in patients with non-alcoholic …

2020

Abstract Background and aim Increased intestinal permeability plays a key role in the pathogenesis of fat deposition in the liver. The aim of our study was to assess whether a single nucleotide polymorphism of protein tyrosine phosphatase non-receptor type 2 (PTPN2) (rs2542151 T→G), involved in intestinal permeability, may be associated with non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM). Methods and results We recruited a prospective cohort of NAFLD subjects and matched controls. Clinical data, PTPN2 genotype and laboratory data were collected for each patient. Results were stratified according to liver histology and diabetes. We enrolled 566 cases and 377 co…

Liver CirrhosisMaleEndocrinology Diabetes and MetabolismMedicine (miscellaneous)030204 cardiovascular system & hematologySeverity of Illness IndexGastroenterologyLiver disease0302 clinical medicineNon-alcoholic Fatty Liver DiseaseRisk FactorsNonalcoholic fatty liver diseasePrevalenceProspective StudiesProtein Tyrosine Phosphatase Non-Receptor Type 2Nutrition and Dieteticsmedicine.diagnostic_testFatty liverMiddle AgedPhenotypeItalyLiver biopsyFemaleCardiology and Cardiovascular MedicineAdultmedicine.medical_specialtySettore MED/12 - GASTROENTEROLOGIA030209 endocrinology & metabolismIntestinal permeabilityPolymorphism Single NucleotideRisk AssessmentPermeability03 medical and health sciencesInternal medicineDiabetes mellitusmedicineGenetic susceptibilityHumansNonalcoholic fatty liver diseaseGenetic Predisposition to DiseaseGenetic Association Studiesbusiness.industryType 2 Diabetes Mellitusmedicine.diseaseCross-Sectional StudiesDiabetes Mellitus Type 2Intestinal AbsorptionCase-Control StudiesSteatosisSteatohepatitisbusiness
researchProduct